13 April 2022

Supporting Sponsor

Sygnature Discovery have been announced as Partnering Sponsor of the 18th Annual Anglonordic Life Science Conference. 

About Sygnature Discovery
Sygnature Discovery is a world-leading integrated drug discovery and non-clinical solutions provider, offering expertise across a broad range of therapeutic areas and biological target classes.

The battle against disease, and the pioneering mission to improve life and health, should be at the top of the agenda for every society. And early drug discovery is right at the heart of this challenge.

It’s a challenge our scientists have been meeting for decades. For us, our work is powered not just by our love of science, but by the value of what we produce. This work is about people. It’s about giving them a better and a longer life. And that is a powerful motivator for success.

Sygnature Discovery’s particular success in this field is due to a distinctive synergy of chemistry, bioscience, drug metabolism and pharmacokinetics, computational design, and in vivo pharmacology. Our unique approach to laboratory working – with multiple disciplines co-located on the same research site in the same laboratories – is key to our success in advancing our customers’ drug discovery projects into clinical development. When hurdles inevitably arise, we bring together different minds and skill sets to create the spark of innovation we need to overcome them.

This is why drug sponsors know they can turn to us with their hopes and their challenges. From target discovery all the way through to preclinical research, Sygnature has the right approach, the right team, and the right tools to enable success.

Meet Sygnature Discovery during networking at the Anglonordic Life Science Conference on Thursday 5th May 2022.

26 March 2022

Supporting Sponsor
Biocaire have been announced as a Supporting Sponsor of the 18th Annual Anglonordic Life Science Conference. 

About Biocair
Biocair is a global GDP logistics specialist with over 35 years of experience in the pharmaceutical, biotechnology and life sciences sectors.

Biocair has built up a unique, client-centric approach by employing scientists in front-line logistics positions and assembling a team of best-in-class industry experts in quality, cold chain and regulatory compliance.

Biocair focuses on providing the most comprehensive time-sensitive and temperature-controlled logistics services available, whilst delivering flexible, tailored, cost effective solutions to all clients.

Meet Biocair during networking at the Anglonordic Life Science Conference on Thursday 5th May 2022.

24 March 2022

Gold Sponsor

Barrington James have been announced as a Gold Sponsor of the 18th Annual Anglonordic Life Science Conference. Barrington James will also Exhibit and we're delighted to share they will also sponsor the Conference Drinks Reception on Thursday 5th May.

About Barrington James
Barrington James are your global and award winning Life Science recruitment experts. Having grown in both size and reputation since 2002, we now operate across three continents and are at the forefront of recruiting top talent for the most innovative Biotech, Pharmaceutical and Medical Device companies. Known as ‘The girls and guys in the red ties’, our team are highly recognised at our global conferences and we work hard to foster personal relationships that go beyond a professional transaction. ‘We Invest In Our People’ through training and development, through meritocratic progression, and through unrivalled commission structures, shareholder and bonus schemes.

Meet the Barrington James team during networking, Exhibition and The Conference Drinks Reception at the Anglonordic Life Science Conference on Thursday 5th May 2022.

22 March 2022

Keynote Speaker Announced!

Dr Gil Bar-Nahum has been announced as the Keynote Speaker for the 18th Annual Anglonordic Life Science Conference.

About Dr Gil Bar-Nahum
Dr Gil Bar-Nahum is Managing Director in the Global Healthcare Investment Banking Group at Jefferies and is based in London. He leads the Jefferies’ International Biotechnology team with a primary focus on innovative companies in Europe and Israel. Dr. Bar-Nahum has over 18 years of investment banking experience and has executed transactions forbiotechnology, pharmaceutical, medical technology, and life science tools companies. In the last 4 years Dr. Bar-Nahum has led the execution of more than 40 financings, including 17 IPOs for foreign private issuers (12 on NASDAQ), raising more than US$3.2Bn. Since joining Jefferies in 2009, Dr Bar-Nahum has also advised on more than 10 cross-border M&A transactions. From 2002-2009 Dr. Bar-Nahum was part of UBS Investment Bank's Global Healthcare Group, based primarily in the US. Prior to that, Dr. Bar-Nahum worked as an Equity Research Analyst for UBS where he served as an Associate Director covering companies in the Life Science Tools and Biotechnology space. Dr. Bar-Nahum received his PhD in Basic Medical Sciences from the Department of Biochemistry at the Sackler Institute of New York University School of Medicine. The subject of Dr. Bar-Nahum's doctorate work was published twice in the journal Cell. Dr. Bar-Nahum also received an MS from New York University’s School of Medicine in Cell and Molecular Biology and a BS from the University of Illinois in Microbiology.

Dr Gil Bar-Nahum will deliver the Keynote at the Anglonordic Life Science Conference on Thursday 5th May 2022 at 09:05 - 09:30.

22 March 2022

Silver Sponsor

Scantox have been announced as Silver Sponsor of the 18th Annual Anglonordic Life Science Conference.

About Scantox
"We are a Copenhagen based pre-clinical research organization with years of experience in the field of pre-clinical regulatory toxicology. We offer a broad range of services within toxicology, pharmacology, pathology and medical devices. All our staff are highly educated and trained to deliver quality work on time. Whether you are a small biotech company or a large pharma client, you are regarded as a valued partner and we focus on bringing you in contact with our skilled and dedicated scientist as early as possible.

We are fully equipped to handle and formulate test items including radioactive labelled compounds as well as controlled substances. Our clinical pathology and histopathology department take care of dose formulation analysis, blood sample analysis as well as production of tissue slides for our skilled pathologists. In our animal facility, housing and care of animals are performed to high standards to ensure optimal health and welfare for all our animals.

Meet the Scantox team at the Anglonordic Life Science Conference on Thursday 5th May 2022.

11 Mar 2022

Supporting Sponsor

Lonza have been announced as Supporting Sponsor of the 18th Annual Anglonordic Life Science Conference.

About Lonza

As one of the world’s most renowned companies for contract development and manufacturing, we are recognized for our reliable, high-quality service, our global capacity, our innovative technology platforms, and our extensive experience. In 2019 we provided manufacturing services for more than 300 commercial molecules and supported the development of more than 700 pre-clinical and clinical molecules in small and large molecules as well as supporting the launch of pioneering autologous cell therapies.

Success for us is when you, as our partner, are fully satisfied. We continuously improve and innovate to meet your expectations and improve your chances of business success. Our broad capabilities span across biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical stage through to commercialization, and our expertise covers both drug substance and drug product.

Meet Lonza at the Anglonordic Life Science Conference on Thursday 5th May 2022.

28 Feb 2022

Rare Disease Day 2022

Today, the 28th of February marks the annual, global celebration of the rare disease community. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases, about rare diseases and their impact on patients lives.

Over the last month, CRDN has been running its annual awareness-raising campaign through their social media channels, helping to make sure rare diseases are visible and vocal, seen and heard. Their regional Unique Feet community of children and families affected by rare conditions have helped them to share their stories, as this is their day most of all. You can find a collection of the families' stories on their Instagram channel and their website.

Meet Cambridge Rare Disease Network at the Anglonordic Life Science Conference on Thursday 5th May 2022.

05 Jan 2022

Charity of the Year 2022 Announced

The Anglonordic Life Science Conference has announced Cambridge Rare Disease Network (CRDN) as their Charity of the Year for 2022. Conference delegates will have the opportunity to meet CRDN during the conference programme including panel discussions, 1:1 networking and the exhibition.

CRDN is a platform for change. It is the infrastructure that unites patients, advocates, experts and leaders to address the challenges faced by people affected by rare diseases. By sharing knowledge and experience, and working together, the journey towards better diagnosis, treatment and support for patients and their families is smoother and more certain.

Cambridge Rare Disease Network is absolutely delighted to be selected as the Anglonordic Life Science Charity of the Year for 2022! It is a privilege to be given this opportunity to raise our profile and the challenge of rare diseases amongst key industry leaders and companies with a shared passion for innovation in drug discovery and technology." Jo Balfour, Managing Director, CRDN

08 December 2021

Merck KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the expansion of its strategic, corporate venture capital arm M Ventures.

The new investment of € 600 million allocated to M Ventures will be deployed over the next five years. This is the third increase in financial commitment announced by Merck KGaA, Darmstadt, Germany, since the creation of M Ventures in 2009. The increase will be used to further grow both the number and size of investments.

“Over the past decade, M Ventures has established itself globally as a leading partner to the biotech and tech venture ecosystems,” said Belén Garijo, Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany. 

Meet the M Ventures team during the programme and 1:1 networking at the Anglonordic Life Science Conference, Thursday 5th May, County Hall, London.

01 December 2021

BioPartner launches start-up and loyalty membership tiers at discounted rates

Qualifying startups can now get BioPartner membership for only £400 +vat when meeting the following criteria:

• Company/Academic group Created in the past two years
• Has fewer than five employees
• Pre-revenue
• Developing new therapeutic products, technology platforms, or digital medicine technologies
• CRO and Service companies welcome 

New benefits also include 50% off Anglonordic Life Science Conference fees including sponsorship & exhibitor packages - to enable start up members to meet and pitch to investors, and suppliers to exhibit at a low cost rate.

BioPartner are a co-organiser of the Anglonordic Life Science Conference. Meet the team during 1:1 networking on Thursday 5th May, County Hall, London.

01 September 2021

McDermott Will & Emery

FULL-SERVICE POWERHOUSE …EXPERTISE IN THE LIFE SCIENCES AND IP SECTORS. MARKET-LEADING CAPABILITIES ACROSS THE FULL RANGE OF ISSUES, INCLUDING REGULATORY MATTERS AND BOTH COMMERCIAL AND WHITE-COLLAR LITIGATION." Chambers USA 2021

McDermott’s Life Sciences Team will get you closer to your goals. Composed of top lawyers with demonstrated strength across intellectual property, regulatory, transactional and litigation law, their purpose-built team of thought leaders is united by a passion for their work. Their team can meet the legal needs of life sciences companies at every stage of development. For decades, they have embraced the value of focused knowledge, harnessing both the particular skills of individuals and the collective experience of their team.

Meet the McDermott Will & Emery team during the programme and 1:1 networking at the Anglonordic Life Science Conference, Thursday 5th May, County Hall, London.

01 July 2021

Protagen Protein Services Merges with GeneWerk to Integrate Leading Protein and Gene Therapy Analytic Platforms

Protagen Protein Services (PPS) today announced that it will merge with GeneWerk, an Ampersand portfolio company. With the addition of GeneWerk’s unique capabilities in vector safety, characterization, and functionality analysis, PPS will complement its current analytical testing offering in protein characterization identity, purity, potency and capsid loading to become a full-service partner in gene therapy testing for the biopharmaceutical industry.

Today’s announced merger creates a leading partner for the worldwide biopharmaceutical industry to benefit from the most advanced, integrated set of analytical services capabilities in biologic development, especially in gene and cell therapy-related testing, from early development through drug approval to commercialization. The combined organization will have more than 175 employees across four sites in Europe and North America.

Meet the ProtaGene team during 1:1 networking and at their Exhibition stand at the Anglonordic Life Science Conference, Thursday 5th May, County Hall, London.

30 June 2021

Dame Kate Bingham’s Keynote from the 17th Anglonordic Life Science Conference

At the 17th Anglonordic Life Science conference this year Kate Bingham discussed the actions of the VTF, how parties were brought together, and how they tackled the procurement, manufacturing, and distribution challenges they were faced with in what was a triumph of science and global collaboration.

Key takeaways
Time is of the essence – it doesn’t have to be perfect! The previous fastest development of a vaccine from recognition of a disease (measles) to a licensed vaccine in the US was 10 years and there was a clear need to speed up development of COVID-19 vaccines. The Prime Minister stressed that “time is of the essence, it doesn’t have to be perfect!” and set three goals:

• Secure effective COVID-19 vaccines for the UK
• Ensure successful vaccines are distributed internationally to all who need it
• Put plans in place to be better prepared next time around

30 June 2021

If I Knew Then, What I Know Now

Mike Ward, Global Head of Thought Leadership at Decision Resources Group, part of Clarivate, chaired a panel of top industry executives at the Anglonordic Life Sciences Conference: Renee Aguiar-Lucander, CEO Calliditas Therapeutics, Steven Powell, CEO eTheRNA immunotherapies and Roel Bulthuis, Managing Partner at INKEF Capital, shared key decisions that shaped the fate of their various enterprises. What would they do differently and what would they not hesitate to do again? We share top takeaways from this insightful discussion.

IPO your business

• Floating your enterprise is a marathon, not a sprint. It requires building relationships with investors, auditors, lawyers while building the organization internally. You need to have these connections and ‘boots’ on the ground and it takes time to build these relationships.
• Whether or not to IPO in US vs Europe should really be determined by the company’s capital needs, the size and maturity of your business and also your existing shareholder base – the need for crossover investors is important. The ultimate goal is to align the business’s capital allocation strategy with its operational strategy: where are your potential competitors and peer group; where is the addressable market and will you need to set up a commercial organization based in the US?

02 June 2021

Takeaways from EU VCs Panel Discussion

Amber Tong, Senior Editor at Endpoints, chaired a fantastic panel of Europe’s leading VC investors at the Anglonordic conference. The panel included: Hakan Goker – M Ventures; Debbie Harland – SR One; Nanna Lüneborg – Novo Ventures: and Stephan Christgau – EIR Ventures. We have summarised the top takeaways below.

How has the pandemic impacted your business and what is the new normal?

• Despite the pandemic, venture firms have successfully closed funds, exited investments (both through IPOs and M&A) and invested in new and exciting companies.
• For investors who spend a significant time travelling, it has been very efficient and productive to have meetings online. Additionally, it has been tricky, but not impossible, to hire people remotely into a team or a portfolio company.
• Venture Capital is a people driven business relying heavily on relationship building. However, you can witness other, more personal aspects of a colleague’s life with the sudden appearance of a child or a pet to liven up an online meeting – and these instances can help forge close relationships.
• Investors miss face to face meetings, dinners and spontaneous discussions, and for future expect a hybrid of virtual and in-person encounters.

26 May 2021

Building Your Board - PIR International Panel Discussion

PIR International recently hosted a panel of Biotech industry experts on the topic of ‘Building your Board’ during the 17th Anglonordic life science conference, doing a deep dive on all things necessary to set-up a successful Board for all stages of growth.

As anticipated, it was expertly hosted by Maureen Coleman. Maureen was joined by a superb panel of Eva-Lotta Allen, Edwin Moses, Patrick Vink and Melanie Lee. The discussion was tremendously insightful, providing healthy debate and conversation around all aspects of Board composition, diversity, structure, culture and much more.

The utilisation of independent board members, why and when to engage them, and indeed how many does a Board need to ensure a balanced external board level input and yet not to overpopulate the Board, was just one of many chapters of insight from the panel.